Gain Therapeutics (NASDAQ:GANX) Trading 1.6% Higher - Should You Buy?

Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report)'s share price shot up 1.6% during trading on Thursday . The stock traded as high as $1.89 and last traded at $1.88. 188,347 shares were traded during mid-day trading, a decline of 36% from the average session volume of 294,407 shares. The stock had previously closed at $1.85.

Analyst Ratings Changes

GANX has been the topic of several recent research reports. Scotiabank began coverage on Gain Therapeutics in a report on Friday, March 7th. They set a "sector outperform" rating and a $12.00 price objective on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $8.00 target price on shares of Gain Therapeutics in a research report on Monday, March 17th. Finally, Chardan Capital restated a "buy" rating and issued a $6.00 price objective on shares of Gain Therapeutics in a research note on Friday, March 28th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Gain Therapeutics presently has an average rating of "Buy" and a consensus target price of $8.20.

Gain Therapeutics Trading Up 9.0 %

The company has a current ratio of 2.99, a quick ratio of 2.99 and a debt-to-equity ratio of 0.04. The company has a 50 day moving average of $1.93 and a 200 day moving average of $2.07. The firm has a market cap of $58.93 million, a price-to-earnings ratio of -1.86 and a beta of 0.18.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.07. As a group, research analysts anticipate that Gain Therapeutics, Inc. will post -1 EPS for the current year.

Institutional Investors Weigh In On Gain Therapeutics

Several institutional investors have recently modified their holdings of GANX. Marshall Wace LLP acquired a new stake in Gain Therapeutics during the 4th quarter worth $198,000. Geode Capital Management LLC grew its stake in shares of Gain Therapeutics by 48.0% during the third quarter. Geode Capital Management LLC now owns 271,972 shares of the company's stock worth $484,000 after purchasing an additional 88,236 shares during the period. Jones Financial Companies Lllp increased its holdings in Gain Therapeutics by 83.6% in the fourth quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company's stock valued at $212,000 after purchasing an additional 44,750 shares during the last quarter. Northern Trust Corp boosted its holdings in Gain Therapeutics by 88.2% during the fourth quarter. Northern Trust Corp now owns 84,586 shares of the company's stock worth $183,000 after buying an additional 39,642 shares during the last quarter. Finally, Bridgeway Capital Management LLC acquired a new position in shares of Gain Therapeutics during the 4th quarter worth about $65,000. Institutional investors and hedge funds own 11.97% of the company's stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.